cadl stock: Candel Therapeutics (Nasdaq) Guide

CADL (Candel Therapeutics, Inc.)

cadl stock refers to the Nasdaq ticker for Candel Therapeutics, Inc., a clinical‑stage biotechnology company developing viral immunotherapies for solid tumors. This article explains what cadl stock represents, the company's mission and pipeline, clinical trial progress, financial and market metrics, corporate governance, risks, and how to follow updates. The goal is to provide a clear, beginner‑friendly, and source‑backed reference — not investment advice.

Company overview

Candel Therapeutics, trading under the ticker cadl stock on the Nasdaq, is a clinical‑stage biotechnology company focused on viral immunotherapies designed to stimulate anti‑tumor immune responses in patients with solid tumors. Headquartered in Needham, Massachusetts, Candel develops engineered adenoviral vectors and related oncolytic and in‑situ vaccination approaches to treat cancers resistant to standard therapies.

As of January 24, 2026, cadl stock identifies Candel’s publicly traded equity on Nasdaq. This article treats cadl stock explicitly as a stock ticker; it does not relate to cryptocurrencies, tokens, or blockchain assets.

History

• Founding and early research: Candel Therapeutics was founded to advance viral‑based immunotherapies in oncology, building on preclinical research into adenoviral vectors and in‑situ vaccination concepts.
• Clinical program initiation: The company advanced its leading candidates into clinical trials focused on multiple solid tumor indications.
• Financing and public listing: Candel pursued private financing rounds to support R&D and later listed on the Nasdaq under the ticker cadl stock to access public capital and broaden investor participation.
• Strategic collaborations: Over time, the company announced collaborations and licensing agreements to support development, manufacturing and combination therapy strategies.
• Management and governance updates: Candel has periodically updated executive leadership and board composition to align with clinical and commercial objectives.

(For verifiable milestone dates and formal announcements, see company investor relations releases and SEC filings.)

Research and development / Pipeline

Candel's R&D centers on viral immunotherapies that act as an in‑situ vaccine: delivering a therapeutic payload directly into the tumor to recruit and activate the immune system against cancer cells. The pipeline has historically included lead candidates such as CAN‑2409 and CAN‑3110. Below is an overview of primary programs as disclosed by the company and reported by financial news sources.

CAN‑2409

CAN‑2409 is a non‑replicating adenoviral vector that delivers the herpes simplex virus thymidine kinase (HSV‑TK) gene to tumor cells. Administered intratumorally (or via locoregional delivery), CAN‑2409 is followed by a prodrug (e.g., ganciclovir) that is converted by HSV‑TK into a cytotoxic agent locally, resulting in tumor cell death and release of tumor antigens which may prime anti‑tumor immunity.

• Indications: CAN‑2409 has been evaluated in multiple solid tumor types, including prostate cancer, non‑small cell lung cancer (NSCLC), and other indications where locoregional delivery is feasible.
• Development stage: Historically, CAN‑2409 advanced through early‑phase clinical trials. As of recent company reports, the program has produced safety and preliminary efficacy data intended to inform larger trials or registrational strategies.
• Key trial results: Trial readouts published or presented at scientific meetings reported tolerability and signals of immune activation. Specific endpoints and statistical outcomes are reported in company releases and peer‑reviewed or conference materials.
• Regulatory interactions and milestones: The company has engaged with regulatory agencies to discuss development paths, including potential pivotal studies and eventual biologics license application (BLA) or marketing authorization application (MAA) planning, as appropriate.

CAN‑3110

CAN‑3110 is an engineered viral therapy directed at central nervous system tumors, including gliomas. It represents Candel’s approach to delivering immunomodulatory payloads into tumors where systemic therapies have limited penetration.

• Indications: Glioma and other intracranial tumors.
• Development status: CAN‑3110 has been evaluated in early clinical trials, with reported interim safety and biomarker data intended to guide dose selection and expansion cohorts.
• Next steps: The company may pursue additional studies to establish clinical benefit and explore combination strategies with checkpoint inhibitors or other modalities.

(For trial identifiers, sponsor disclosures and primary endpoint details, consult clinicaltrials.gov entries and company press releases.)

Clinical trials and results

Candel has run and reported on several Phase 1/2 trials examining safety, tolerability, immunologic activity and early efficacy signals for both CAN‑2409 and CAN‑3110 across tumor types. Summaries of outcomes typically highlight the following:

• Safety profile: Early‑phase trials emphasize tolerability and manageable adverse event profiles at tested doses.
• Pharmacodynamics and biomarkers: Evidence of immune activation (e.g., T‑cell infiltration, cytokine changes) has been presented to support the proposed in‑situ vaccination mechanism.
• Efficacy signals: Objective responses and disease control rates in small cohorts have been used to justify further development, though larger controlled trials are required to establish definitive efficacy.

As of January 24, 2026, according to company disclosures and meeting abstracts reported by scientific conferences, ongoing trials include expansion cohorts and combination studies designed to define optimal regimens and support later‑stage development.

Business model and strategy

Candel’s business model reflects typical clinical‑stage biotech strategy:

• R&D focus: Invest in translational research and clinical development to advance lead candidates through proof‑of‑concept and into registrational trials.
• Partnerships: Pursue collaborations for combination therapies, manufacturing scale‑up, and region‑specific commercialization where appropriate.
• Commercialization approach: Depending on late‑stage outcomes and resource availability, Candel may commercialize internally in select markets or partner/license programs to larger oncology companies with established sales and distribution networks.

The company positions its viral immunotherapy approach as a potential complement to existing immuno‑oncology agents, aiming to convert immunologically “cold” tumors into “hot” tumors that respond to checkpoint blockade and other immune therapies.

Financials

Candel, as a clinical‑stage biotech, historically had limited or no product revenue and relied on capital markets, grants, and collaborations to fund R&D and operations. High‑level financial considerations for cadl stock investors and followers include:

• Revenue profile: Primarily pre‑revenue or limited revenue from collaborations; R&D expenses represent the largest cash outflow.
• Cash position and runway: The company periodically reports cash, cash equivalents, and short‑term investments that determine operational runway. Financing events (equity offerings, debt facilities, convertible instruments) affect dilution and liquidity.
• Recent financings: Candel has used common mechanisms (registered offerings, private placements, ATM offerings or debt arrangements) to extend runway and fund trials; check the latest SEC filings for transaction specifics.

As of January 24, 2026, according to company SEC filings and investor relations reports, Candel’s most recent quarterly filing reported cash and equivalents intended to fund operations into the near‑to‑mid term, subject to standard clinical development uncertainties. For precise figures (cash balance, quarterly R&D spend, operating loss), review the company’s most recent Form 10‑Q or 10‑K.

Stock information

• Ticker and exchange: cadl stock trades on the Nasdaq.
• Market capitalization: Market cap fluctuates with share price and outstanding shares. As of January 24, 2026, financial data providers reported market capitalization within a small‑cap biotech range (see Nasdaq and Yahoo Finance for exact, real‑time values).
• Trading characteristics: cadl stock typically shows trading volume and volatility common to clinical‑stage biotech stocks — activity often spikes around clinical readouts, financing announcements, or meaningful collaborations.
• Identifiers: For official identifiers like CUSIP and ISIN, check the company’s investor relations or broker quote pages.

Trading history and performance

cadl stock price movements historically reflect news flow from clinical data releases, regulatory interactions, financing events, and broader market trends in biotechnology. Notable drivers of volatility include:

• Clinical readouts and conference presentations.
• Financing announcements that dilute existing shareholders.
• Regulatory communications or unexpected safety signals.

As of January 24, 2026, according to Nasdaq and Yahoo Finance reporting, cadl stock’s 52‑week high/low and recent trading volume are available on quote pages; those metrics are dynamic and should be checked on live quote services for trading decisions.

Analysts and ratings

Coverage of cadl stock by sell‑side analysts may be limited compared with large‑cap names. Analyst reports, if available, typically discuss trial readouts, partnership potential and cash runway, and may express buy/hold/sell views based on clinical progress and financing needs. For up‑to‑date analyst coverage and price targets, consult institutional research platforms disclosed in press releases or financial news pages.

Major corporate events and recent developments

As a clinical‑stage company, Candel routinely issues press releases and files SEC disclosures regarding clinical milestones, interim data, financing actions, and corporate events. Examples of the types of events that materially affect cadl stock include:

• Interim clinical data presentations at medical conferences.
• Initiation or completion of patient enrollment in trials.
• Announcements of strategic partnerships or licensing agreements.
• Equity or debt financings and any changes to capital structure.
• Executive hires or departures and governance changes.

As of January 24, 2026, according to company press releases and SEC filings, Candel reported ongoing trial activity and standard corporate updates. For the precise chronology and text of each announcement, consult the investor relations news archive and the company’s SEC filing history.

Corporate governance and leadership

Candel’s governance structure includes a board of directors and executive leadership team responsible for scientific strategy, operations and financial stewardship. Typical disclosures list the CEO, CFO, Chief Medical Officer, and other senior leaders along with board committee structures. Scientific advisors and academic collaborators often support clinical program design and translational research.

For current names and biographies, consult the company’s investor relations leadership page and proxy statements filed with the SEC.

Shareholder structure and ownership

Institutional investors, mutual funds, and biotech‑focused managers may hold stakes in cadl stock, while insiders (executive officers and directors) typically hold restricted shares or stock options. Ownership concentration, major institutional holders and insider transactions are disclosed in SEC filings and on financial data platforms.

As of January 24, 2026, according to public filings summarized by financial data providers, institutional ownership accounts for a meaningful portion of outstanding shares, while insider ownership reflects management and board compensation structures. For exact percentages and shareholder names, review the company’s latest 13F and Schedule 13D/G filings where applicable.

Risk factors

Investors and followers should consider the typical risks associated with a clinical‑stage biotechnology company trading as cadl stock:

• Clinical and regulatory risk: Lead candidates may fail to demonstrate safety or efficacy in larger, controlled trials, or regulators may request additional data or modifications.
• Financing and dilution risk: Continued development requires capital; future financing rounds may dilute existing shareholders.
• Competitive risk: Other companies developing immuno‑oncology or oncolytic viral therapies may offer competing approaches or superior results.
• Manufacturing and scalability: Complex biologics manufacturing can present production and cost challenges for commercialization.
• Market and liquidity risk: As a small‑cap biotech, cadl stock can experience significant price volatility and lower liquidity during periods of limited news flow.

This section is factual and not investment advice. For a full list of risks, consult the company’s most recent Form 10‑K and proxy materials.

Legal and regulatory matters

Candel discloses any material legal proceedings, regulatory communications and material agreements in its SEC filings. Known regulatory interactions generally relate to clinical trial approvals, IND/CTA submissions, and routine correspondence with agencies. Material litigation, if any, is filed in the company’s legal proceedings disclosures.

As of January 24, 2026, no widely reported material litigation or regulatory sanctions had been announced in primary company disclosures, per investor relations and SEC filing summaries. Verify active or new matters by checking the company’s real‑time SEC filing feed.

Market reception and investor community

cadl stock attracts attention from the biotech investor community, including institutional investors, scientific investors and retail participants. Social platforms such as StockTwits may show active retail discussion around clinical milestones and stock moves. Financial media outlets (Yahoo Finance, Reuters, Nasdaq pages) publish quotes, news summaries and analyst commentary that inform market perception.

As of January 24, 2026, according to social sentiment trackers and finance news pages, cadl stock shows the typical episodic spikes in retail interest around data releases and financings. Institutional interest is often reflected in reported 13F filings and press‑reported stakes.

See also

• Viral immunotherapy
• In‑situ vaccination
• Clinical‑stage biotechnology
• Oncolytic virus therapies

References

Below are the types of authoritative sources on which this guide relies; use the company’s investor relations and SEC filings for primary documents and official figures:

• Company investor relations announcements and SEC filings (10‑Q, 10‑K, 8‑K)
• Nasdaq and Yahoo Finance quote and company pages for market data and identifiers
• Reuters/ LSEG company metrics and business summaries
• Major brokerage pages and research notes consolidating public filings
• Clinical trial registries and conference abstracts for trial design and results
• StockTwits and other social sentiment aggregators for retail interest indicators

Specific reporting notes:

• As of January 24, 2026, according to Nasdaq and Yahoo Finance quote pages, cadl stock is listed and actively traded on Nasdaq. (Source: Nasdaq, Yahoo Finance — market quote pages, reported January 24, 2026.)
• As of January 24, 2026, Reuters and MSN summarized company key metrics and recent press releases in corporate profile pages. (Source: Reuters corporate key metrics, MSN company page — reported January 24, 2026.)

External links

• Official company investor relations page and primary SEC filings are the authoritative sources for corporate and financial disclosures.

How to follow cadl stock and next steps

If you want to monitor cadl stock developments:

• Follow the company investor relations news feed and sign up for press release alerts.
• Check SEC filings (10‑Q, 10‑K, 8‑K) for formal disclosures on financings, clinical data and risk factors.
• Track clinical trial registries and conference programs for abstracts or presentations tied to CAN‑2409 and CAN‑3110.
• Use reputable financial quote services (Nasdaq, Yahoo Finance, Reuters) for real‑time price, volume and market cap updates.

If you plan to trade cadl stock, consider trading through reputable brokerages and platforms. For users seeking a trading venue with derivatives, spot trading and fiat on‑ramps, Bitget offers market access and tools for traders. This is a platform reference and not an endorsement of any specific trading decision.

Note: All factual statements in this article are based on primary disclosures and major financial data aggregators as of their reported dates. For the most recent quantitative metrics (market cap, daily volume, outstanding shares), consult real‑time quotes and the company's SEC filings. This article is educational in nature and not investment advice.